Just out in @Cancers, nice internat collabor 🇬🇷🇸🇪🇮🇹🇺🇸 reviewing recent advances on overcoming #resistance in #EGFR mutant #NSCLC Karolinska Institutet EGFRm NSCLC EGFR Positive Lung Cancer UK EGFR Resisters ΕΛΛΟΚ Grateful 🙏 Andreas Koulouris Giulio Metro @ all authors 👏 #some #LCSM Chat OncoAlert

Advanced non-small-cell lung cancer: how to manage EGFR & HER2 exon 20 insertion mutation-positive disease Giulio Metro Andrea De Giglio, MD PhD @BiagioMd marco siringo Daniele Marinelli Luca Cantini Giuseppe Lamberti Giannis Mountzios et al #drugsincontext #nsclc #oncology drugsincontext.com/advanced-non-s…

🎗 Oggi, 1º Agosto, si celebra la Giornata Mondiale per il Tumore del Polmone. #WorldLungCancerDay

Non-small-cell lung cancer: how to manage EGFR-mutated disease Federica Pecci Luca Cantini Giulio Metro @BiagioMd Giuseppe Lamberti et al. #drugsincontext #nsclc #oncology #cancer #tki #antibodytherapeutics drugsincontext.com/non-small-cell…

Activity of #osimertinib in #nsclc with uncommon #EGFR mutations. It’s a pleasure to share the first data of multicenter #Articuno study at #WCLC22 #LCSM

🚨 First-time ever KRAS-mutant cancer can be targeted. #LCSM Phase 3 CodeBreak-200 trial Met Primary Endpoint of Progression-Free Survival, Sotorasib Superiority Over Standard of Care Docetaxel Chemotherapy, in KRAS G12C-Mutated Non-Small Cell Lung Cancer amgen.com/newsroom/press…

#ResearchDayInsight Dr Arsela Prelaj arsela prelaj, Dep of Medical Oncology 1, Thoracic Tumors Unit, about👇 #Apollo11 👉an Italian #Network for advanced #lungcancer patients treated with #innovative therapies 💊 #LCSM #PrecisionMedicine #CancerResearch

#ESMO22 OncoAlert 🚨 The much-waited 4-year data of ADAURA: ➡️mDFS:65.8 m vs 21.9m HR=0.23 ➡️HR=0.24 for CNS, 2% probability of CNS relapse at 3 years with OSI ➡️QTc prolong in 9% OSI interrupted at 3 years and curve drops sharply after this landmark, so maybe continue beyond?

Apollo 11 Network on #Lung #Cancer patients treated with #Innovative therapies… a big Italian Effort on #realWorld data and #traslational research and #big data analysis! We finally Meet in person AIOM this year! Gius ♡ giuseppe viscardi Giulio Metro Carlo Genova Elio Gregory Pizzutilo

New in @DrugsinContext Non-small-cell lung cancer: how to manage ALK-, ROS1- and NTRK-rearranged disease Daniele Marinelli marco siringo Giulio Metro @BiagioMd Gelibter #drugsincontext #nsclc #oncology #lungcancer #treatment drugsincontext.com/non-small-cell…

UNICORN: An international real-world study of #osimertinib for uncommon #EGFR mutations as a first line setting further clarifies the drug's impact in patients with uncommon EGFR mutations. bit.ly/3StwroQ #LCSM Jair Bar Martin Reck Hochmair Maximilian Sandip Patel MD FASCO @ShiruOnc

Resistance to specific RET inhibitors is quite heterogeneous, with only 14% on-target resistance mechanisms. Large study in 100+ patients on primary and secondary resistance. It will not ease the development of 2nd gen inhibitors! #ENA2022 Mihaela Aldea Arianna Marinello, MD

New Drugs in Context How to manage KRAS G12C-mutated advanced non-small-cell lung cancer @BiagioMd Federica Pecci Luca Cantini Andrea De Giglio, MD PhD Giuseppe Lamberti Giulio Metro et al. drugsincontext.com/how-to-manage-… #drugsincontext #nsclc #oncology #lungcancer #mutations #cancertreatment

🚨When Academia collaborates👩‍🎓👨‍🎓 rare tumors come to light💡! Just out in JTO & JTO CRR large RWD on #Exon20 #EGFRmut #NSCLC (175 pts, 10 countries) Kudos to all authors for collecting 1 by 1 case PS: Zero budget💶! OncoAlert #some #LCSM Exon 20 Group, a multistakeholder organization sciencedirect.com/science/articl…

David Planchard Giulio Metro arsela prelaj @walidshalata Nicolas Girard Víctor Albarrán-Artahona charocampelo Giuseppe Banna IOANNIS BOUKOVINAS Abed Agbarya Helena Linardou Ilias Athanasiadis @korangr Alexandros Ardavanis Emmanouil Saloustros Amanda Psyrri Martin Reck

RET-MAP: 31 centers united efforts to characterize rare RET NSCLC. RETi significantly improve survival vs historical cohorts. Haute Autorité de santé: lack of RETi outside trials costs lives. Action needed for RETpositive Benjamin Besse Arianna Marinello, MD JTO & JTO CRR jto.org/article/S1556-…

💡🚨Just out in JTO & JTO CRR the final analysis of the #EXOTIC RWD registry on rare #EGFRexon20 muts in 175 #NSCLC pts. Hope will provide useful RWD in this rare dis. entity.🙏 to all authors for collecting pts 1 by 1,#Academia rocks! IASLC d.planchard #LCSM #some OncoAlert

Almost all tumors are technically resectable - the question is “should we resect?” Perhaps more so than converting tumors, we need to convert physicians with an “unresectable” first mentality to a “resectable” mentality. #lcsm #TexasLung23